• AAPL 169.89
  • TSLA 170.18
  • AMZN 173.67
  • MSFT 399.04
  • INTC 35.11
  • EURUSD 1.0726
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. PA /
  3. ALACT.PA

Acticor Biotech SAS (ALACT PA) stock market data APIs

€0.46 0.19(70.4%) as of April 25, 2024

Acticor Biotech SAS Financial Data Overview

0.74
0.46
-
0.401
-0.13
0.27-6.22
4 489 K
15 686 K
1 736 K
0
-0.382
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'ALACT',
Type: 'Common Stock',
Name: 'Acticor Biotech SAS',
Exchange: 'PA',
CurrencyCode: 'EUR',
CurrencyName: 'Euro',
CurrencySymbol: '€',
CountryName: 'France',
CountryISO: 'FR',
ISIN: 'FR0014005OJ5',
CIK: NULL,
EmployerIdNumber: '',
FiscalYearEnd: 'December',
IPODate: NULL,
InternationalDomestic: 'International',
Sector: 'Healthcare',
Industry: 'Biotechnology',
}

Acticor Biotech SAS Fundamental Data is available in our Financial Data APIs

  • Net Revenue 1 736 K
  • EBITDA -16 678 000
  • Earnings Per Share -1.67
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Acticor Biotech SAS Earnings via APIs

  • Latest Release 2024-03-22
  • EPS/Forecast 0

Get Acticor Biotech SAS End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Acticor Biotech SAS latest news via APIs

Acticor Biotech has just and timely completed patient recruitment of its phase 2/3 study in stroke

Acticor Biotech has just and timely completed patient recruitment of its phase 2/3 study in stroke 438 patients with stroke have been randomized in ACTISAVE study evaluating glenzocimab, in the Unite...
  • ACTICOR BIOTECH
  • CLINICAL STUDY
  • PARIS STOCK EXCHANGE:ALACT

Acticor adapts its ACTISAVE clinical study to prepare the registration of glenzocimab for the treatment of stroke

ACTICOR adapts its ACTISAVE clinical study to prepare the registration of glenzocimab for the treatment of stroke Clinical results from ACTISAVE phase 2/3 study now expected in the second quarter of ...
  • ACTICOR BIOTECH
  • HEALTH
  • PARIS STOCK EXCHANGE:ALACT
Do you have any questions?
support@eodhistoricaldata.com